Last updated 47 hours ago
A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
160 patients around the world
Available in United States, Chile, Brazil, Argentina
Bristol-Myers Squibb
160Patients around the world
This study is for people with
Lung cancer
Non-small cell lung carcinoma
Requirements for the patient
From 18 Years
All Gender
Medical requirements
- Participants must have histologically confirmed diagnosis of stage IV non-small cell lung cancer (NSCLC) (squamous or non-squamous) or recurrent unresectable disease per the American joint committee on cancer (AJCC) Staging System 9th edition.Participants must have no prior systemic anti-cancer therapy given as primary therapy for advanced or metastatic disease.Tumor tissue (fresh or archival) obtained within 5 months of enrollment (signing of informed consent) for each participant must be submitted by the site.Participants must have an Eastern Cooperative Oncology Group Performance Status of 0 or 1.Participants must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
- Participants must not have any documented actionable genomic alterations (AGAs) for which first line approved targeted therapies are indicated.Participants must not have prior treatment with immuno-oncology therapies.Participants must not have untreated central nervous system (CNS) metastases.Other protocol-defined Inclusion/Exclusion criteria apply.
SponsorBristol-Myers Squibb
Study typeInterventional
Conditions
Non-small cell lung carcinoma
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT07680764
